Hence, these data highlight an interesting dual mechanism of action for SCO-101 as inhibitor, also contributing to overcoming the difficulty in developing UGT inhibitors with low toxicity [55] and underscoring the relevance of targeting UGT1A1 in cancer as well [30,31]. The gene discussed is SLC35A2; the disease is cancer.